Who are CMAB009 plus Irinotecan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cmab009-plus-irinotecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

CMAB009 plus Irinotecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CMAB009 plus Irinotecan (CMAB009 plus Irinotecan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor and topoisomerase I inhibitor. Area: Oncology.

phase 2 PD-1 inhibitor and topoisomerase I inhibitor PD-1 and topoisomerase I Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CMAB009 plus Irinotecan (CMAB009 plus Irinotecan) — Shanghai Zhangjiang Biotechnology Limited Company. CMAB009 is a PD-1 inhibitor, and Irinotecan is a topoisomerase I inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CMAB009 plus Irinotecan TARGET	CMAB009 plus Irinotecan	Shanghai Zhangjiang Biotechnology Limited Company	phase 2	PD-1 inhibitor and topoisomerase I inhibitor	PD-1 and topoisomerase I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor and topoisomerase I inhibitor class)

Shanghai Zhangjiang Biotechnology Limited Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CMAB009 plus Irinotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/cmab009-plus-irinotecan. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing